Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.52 |
| ▸ | RAF1 | P04049 | 11/20 | 0.48 |
| ▸ | BRAF | P15056 | 9/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.48 |
| ▸ | RET | P07949 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | MAP3K20 | Q9NYL2 | 4/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.48 |
| ▸ | KIT | P10721 | 3/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.48 |
| ▸ | FLT1 | P17948 | 3/20 | 0.48 |
| ▸ | EPHA1 | P21709 | 3/20 | 0.48 |
| ▸ | TTK | P33981 | 3/20 | 0.48 |
| ▸ | FLT4 | P35916 | 3/20 | 0.48 |
| ▸ | FLT3 | P36888 | 3/20 | 0.48 |
| ▸ | CLK1 | P49759 | 3/20 | 0.48 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.48 |
| ▸ | CDK17 | Q00537 | 3/20 | 0.48 |
| ▸ | TEK | Q02763 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5060202 | 0.89 | ABL1 (0.56) | ABL1RAF1BRAFMAPK14RET | |
| SCHEMBL5055284 | 0.88 | MAPK14 (0.55) | BRAFMAPK14KDRMAPK13 | |
| SCHEMBL5055043 | 0.88 | MAPK14 (0.46) | BRAFMAPK14KDRMAPK13 | |
| SCHEMBL5052152 | 0.86 | MAPK14 (0.44) | BRAFMAPK14KDRMAPK13 | |
| SCHEMBL5059912 | 0.85 | ABL1 (0.52) | ABL1RAF1BRAFMAPK14RET | |
| SCHEMBL2025081 | 0.85 | BRAF (0.62) | ABL1RAF1BRAFMAPK14RET | |
| SCHEMBL5056249 | 0.84 | KDR (0.41) | MAPK14KDRFLT1AXLMAPK13 | |
| SCHEMBL5056448 | 0.84 | ABL1 (0.54) | ABL1RAF1BRAFMAPK14RET | |
| SCHEMBL5059976 | 0.83 | ABL1 (0.52) | ABL1RAF1BRAFMAPK14RET | |
| SCHEMBL5052218 | 0.83 | ABL1 (0.52) | ABL1RAF1BRAFMAPK14RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | ABL1 20/4885RAF1 55/4885BRAF 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.